BTN1A1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, designed for targeted disruption of the BTN1A1 gene. This product provides a heterogeneous pool of cells with loss-of-function mutations in BTN1A1, generated by CRISPR/Cas9-mediated gene disruption. The polyclonal format offers population-level diversity, making it suitable for functional studies while reducing clone-specific artifacts.
The A-549 parental cell line is a widely established human lung adenocarcinoma model derived from a 58-year-old male patient. These cells exhibit an adherent epithelial morphology and retain characteristics of alveolar type II pneumocytes, including the ability to form confluent monolayers with tight junctions. A-549 cells are commonly employed as a pulmonary epithelial model for studies of drug transport, signaling, and cancer biology. Their malignant phenotype, combined with a defined genetic background, makes them a reproducible system for evaluating gene function in non-small cell lung cancer (NSCLC).
BTN1A1 (butyrophilin subfamily 1 member A1) is an immunoglobulin superfamily immune checkpoint molecule that inhibits T cell proliferation and cytokine production. It interacts with CD28 and CTLA-4, and signals through the adaptor DAP12 to modulate PI3K-Akt and NF-??B pathways. Upstream, IFN-?? and IL-2 upregulate BTN1A1 via STAT1. Knockout of BTN1A1 therefore abrogates this co-inhibitory signaling, resulting in enhanced T cell activation, increased IL-2 and IFN-?? secretion, and sustained ERK activity. This positions BTN1A1 downstream of cytokine stimulation and upstream of TCR-mediated effector functions, with cross-talk to the CD28/CTLA-4 axis.
In A-549 lung adenocarcinoma cells, BTN1A1 expression may contribute to immune evasion by suppressing anti-tumor T cell responses. Disruption of BTN1A1 in this model creates a system to study how loss of this checkpoint alters the immunogenicity of lung cancer epithelial cells. Co-culture experiments with knockout A-549 cells and T cells can recapitulate aspects of the tumor-immune synapse, allowing dissection of molecular determinants of T cell inhibition. Given the aggressive nature of NSCLC and the limited efficacy of current immunotherapies in certain patient subsets, this knockout model provides a valuable platform for identifying alternative checkpoints and testing combination strategies.
This BTN1A1 knockout polyclonal cell product is suitable for immune-oncology applications including T cell co-culture with ELISA measurement of IL-2 and IFN-??, T cell proliferation assays, and flow cytometric analysis of activation markers such as CD25 and CD69. The cells can also be employed in drug screening for BTN1A1 pathway inhibitors, RNA-seq for transcriptomic profiling, or RT-qPCR and western blotting to confirm target gene disruption. Migration assays may assess metastatic potential. For further technical details, please contact Ascent Research.
